UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/555,664	11/04/2005	Peter Assaf	30724	9895
	7590 12/08/200 OYNIHAN d/b/a PRT	EXAMINER		
P.O. BOX 16446			LOEWE, SUN JAE Y	
ARLINGTON, VA 22215			ART UNIT	PAPER NUMBER
			1626	
			MAIL DATE	DELIVERY MODE
			12/08/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	I				
	Application No.	Applicant(s)			
	10/555,664	ASSAF ET AL.			
Office Action Summary	Examiner	Art Unit			
	SUN JAE Y. LOEWE	1626			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on <u>09 Nation</u>	<u>ovember 2009</u> .				
2a) This action is FINAL . 2b) ☑ This	This action is FINAL . 2b)⊠ This action is non-final.				
·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.			
Disposition of Claims					
4) Claim(s) 6,17,32,33 and 65-75 is/are pending i 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 6,32,33,65-75 is/are rejected. 7) Claim(s) 17 is/are objected to. 8) Claim(s) are subject to restriction and/or	wn from consideration.				
Application Papers					
9)☐ The specification is objected to by the Examine	r.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attach					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Neterlandes Cried (170-092) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate			
0.5.1.1.7.1.1.000					

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 9, 2009 has been entered.

Terminal Disclaimer

2. The terminal disclaimer filed on November 9, 2009 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US 7,189,750 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Response to Amendment

3. The outstanding ground of rejection has been obviated and is thus hereby withdrawn. The search and examination was extended. Prior art was found that anticipates non-elected species wherein X=thiazole. Therefore, the Markush claims were rejected and species outside of the subgenus wherein X=pyridine were held withdrawn from further consideration. Applicant will be entitled to rejoinder of non-elected species upon allowability of the generic claims.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

Art Unit: 1626

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

4. Claims 6, 33 and 65-95 rejected under 35 U.S.C. 102(e) as being anticipated by Thatcher

et al. The reference teaches the following compounds as pharmacological agents.

```
854925-90-9 CAPLUS
     5-Thisroleethanol, 4-methyl-2-(1-(mitrooxy)-1-(3-thiemyl)ethyl)-,
     5-nitrate (CA INDEX NAME)
     854525-94-3 CAPLUS
RN
     2,5-Thiazolediethanol, 4-methyl-81-3-thienyl-, dimitrate (ester) (SCI) (CA INDEX NAME)
                    082-082-0-NO2
    854928-93-8 CAPLUS
     5-Thianoleethanoi, 4-methyl-2-(2,2,3-trifluoro-1-(3-thienyl)ethyl)-, 5-mitrate (CA INDEX WAME)
                    CH2 - CH2 - O- NO2
    854936-03-6 CAPLUS
     Methanone, (4,5-dimethyl-2-thiazolyl) (4-methyl-5-(2-(nztrocky)ethyl)-2-thiazolyl)- (CA INSEX NAME)
```

Application/Control Number: 10/555,664

Art Unit: 1626

Claim Rejections - 35 USC § 103

Page 4

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459

(1966), that are applied for establishing a background for determining obviousness under 35

U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 5. Claim 32 rejected under 35 U.S.C. 103(a) as being obvious over Thatcher et al.

Determination of the scope and contents of prior art.

The reference the compound above, RN 854925-90-9.

Ascertaining the differences between prior art and instant claims.

The following modification to the prior art compound results the instant compound of Pet-95: H vs. Methyl replacement.

<u>Resolving the level of ordinary skill in the pertinent art – Prima Facie Case of Obviousness.</u>

To those skilled in chemical art, one homologue is not an advance over an adjacent member of a homologous series. The reason for this is that one of ordinary skill, knowing the properties of one member of series, would know what properties to expect in adjacent members. In re Henze, 85 USPQ 261 (1950). In re Wood, 199 U.S.P.Q. 137 (C.C.P.A. 1978) and In re Lohr, 137 U.S.P.Q. 548, 549 (C.C.P.A. 1963).

One of ordinary skill would be motivated, from the prior art disclosure to make the modification required to arrive at the instant invention with reasonable expectation of success for obtaining an additional compound for the same utility. The motivation would be to make additional compounds with pharmacological utility.

Thus, the instant claims are *prima facie* obvious over the teaching of the prior art.

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE Y. LOEWE whose telephone number is (571)272-9074. The examiner can normally be reached on M-F 7:30-5:00 Est.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571)272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sun Jae Y. Loewe/ 12-4-2009